| Description |
1 online resource (171 pages) |
| Series |
Hematologic Malignancies |
|
Hematologic malignancies (Series)
|
| Contents |
Intro; Contents; Part I: Pathophysiology; 1: Chronic Lymphocytic Leukemia: Who, How, and Where?; 1.1 Introduction; 1.2 Who; 1.2.1 Genetic Predisposition to CLL; 1.2.2 Monoclonal B-Cell Lymphocytosis; 1.2.3 Cell of Origin; 1.3 How; 1.3.1 Mechanisms of Leukemogenesis; 1.3.2 Genetic Defects; 1.3.3 B-Cell Receptor; 1.4 Where; 1.4.1 Microenvironmental Stimuli; 1.4.2 Cellular Components; 1.5 Conclusions; References; Part II: Diagnostics; 2: Laboratory Diagnosis of Chronic Lymphocytic Leukaemia; 2.1 Introduction; 2.2 Full/Complete Blood Count; 2.3 Morphology; 2.4 Immunophenotype |
|
2.5 CLL Diagnostic Algorithms Based on Immunophenotype 2.5.1 CLL Scoring Systems; 2.5.2 ERIC/ESCCA Approach to Improving Diagnostic Reproducibility; 2.6 Molecular Diagnostics; 2.6.1 Chromosomal Deletions and Aneuploidy; 2.6.2 Chromosomal Translocations; 2.6.3 The Immunoglobulin Gene; 2.6.4 Other Molecular Abnormalities; 2.7 Differential Diagnosis; 2.7.1 Mantle Cell Lymphoma; 2.7.2 B-Prolymphocytic Leukaemia; 2.7.3 Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma; 2.7.4 Cold Agglutinin Disease (CAD); 2.7.5 Monoclonal B-Cell Lymphocytosis |
|
2.8 Richter's Syndrome/Large Cell Transformation 2.9 Summary; References; Part III: Clinical Presentation; 3: The Clinical Presentation of CLL; 3.1 Introduction; 3.2 Demographics; 3.2.1 Incidence; 3.2.2 Age Distribution; 3.2.3 Gender; 3.3 Clinical Features; 3.3.1 Presentation; 3.3.2 Lymphoid Involvement; 3.3.3 Extramedullary Features; 3.3.4 Constitutional Symptoms; 3.3.5 Second Malignancies; 3.4 Laboratory Investigations; 3.4.1 Full Blood Count; 3.4.2 Other Blood Tests; 3.4.3 Bone Marrow (BM) Examination; 3.4.4 Imaging Tests; 3.4.5 Cytogenetics/Molecular Investigations |
|
4.3.9.1 Recurrent Acquired Single Nucleotide Variants (SNV) in CLLNOTCH1; SF3B1; 4.3.9.2 Hierarchical Model Integrating Prognostic Information from Genomic Studies; 4.3.9.3 Predicting the Risk of High-Grade Transformation; 4.4 Prognostic Markers in the Era of Novel Therapies; 4.5 Outlook; References; Part V: Treatment; 5: Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update; 5.1 Introduction |
| Summary |
This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed |
| Notes |
5.2 Clinical Relevance of Genetic or Genomic Alterations Found in CLL, Including Mutations of the TP53 Gene |
|
Online resource; title from digital title page (viewed on May 22, 2019) |
| Subject |
Chronic lymphocytic leukemia.
|
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Chronic lymphocytic leukemia
|
| Form |
Electronic book
|
| Author |
Hallek, Michael, editor.
|
|
Eichhorst, Barbara, editor.
|
|
Catovsky, D. (Daniel), editor.
|
| ISBN |
9783030113926 |
|
3030113922 |
|
149398876X |
|
9781493988761 |
|
3030113914 |
|
9783030113919 |
|
9783030113933 |
|
3030113930 |
|
